The adenoviral E4orf4 protein - A multifunctional protein serving as a guide for treating cancer

Sep 21, 2026

Adenoviral E4orf4 disrupts multiple host regulatory pathways to support viral infection, yet it also functions independently as a potent anti-cancer agent. In cancer cell lines, E4orf4 selectively induces cell killing while sparing non-cancerous cells and eliminates cancer in an in vivo Drosophila model with limited impact on normal tissues. The study provides a proof-of-principle that an E4orf4-mimicking cocktail using sublethal doses of four FDA-approved drugs enhances cancer cell death across many cancer types without toxicity in non-cancerous cells.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages12

Reading Time30 min

AccessFree to download

Introduction

Cancer prevalence and therapeutic progress

Targeted therapies and oncolytic viruses

Tumour Virus Research 19 (2025) 200303 Contents lists available at ScienceDirect Tumour Virus Research journal [homepage:](homepage: www.journals.elsevier.com/tumour-virus-research)[ www.journals.elsevier.com/tumour-virus-research](homepage: www.journals.elsevier.com/tumour-virus-research) | The adenoviral E4orf4 protein: A multifunctional protein serving as a guide for treating cancer, a multifactorial disease
*
Amir Basis , Rakefet Sharf , Tamar Kleinberger
Dept. of Molecular Microbiology, The Rappaport Faculty of Medicine and Research Institute, Technion-Israel Institute of Technology, Haifa, Israel | | | | --- | --- | --- | | A R T I C L E I N F O | | A B S T R A C T | | Keywords: Adenovirus E4orf4
Virus-host interactions Cancer therapy
Drug cocktail | | Viruses exploit several cellular pathways to support their replication, and many of these virus-targeted pathways are also important for cancer growth. Consequently, studying virus-host interactions offers valuable insights into tumorigenesis and can suggest the development of novel anti-cancer therapies, with oncolytic viruses being one well-known example. The adenovirus E4orf4 protein, which disrupts several host regulatory pathways to facilitate viral infection, also functions as a potent anti-cancer agent when expressed independently. E4orf4 can selectively kill a wide range of cancer cell lines while sparing non-cancerous cells. Moreover, it effectively eliminated cancer in an in vivo Drosophila model without causing significant harm to normal tissues.
In this study we provide evidence that an E4orf4-mimicking drug cocktail, comprising sublethal doses of four FDA-approved drugs targeting the pathways disrupted by E4orf4, significantly enhanced cancer cell death in many cancer cell types compared with individual drugs or less inclusive drug combinations. The quadruple drug cocktail was not toxic in non-cancerous cells. These findings provide a proof-of-principle for the potential application of virus-host interaction studies to design an effective E4orf4-based cancer therapy. Further investigation of E4orf4 interactions with the host cell will likely improve this E4orf4-based therapy by adding drugs that disrupt additional pathways.
Crucially, the E4orf4-based approach offers a strategic advantage by avoiding the time-consuming development of novel drugs. Instead, it leverages existing drugs, including those that might be too toxic for use as monotherapies, by employing them at sublethal concentrations in combination. Thus, it provides a feasible and efficient method for advancing cancer therapy. | 1. Introduction Cancer has plagued humanity for millennia, with historical records dating back to ancient times, documenting its impact on human health [1]. In recent years, the global prevalence of cancer has increased significantly, driven by factors such as environmental influences, lifestyle choices, and the increasing average human lifespan [2]. This rise in cancer cases was accompanied by significant advances in our understanding of the disease, which have come a long way since the early days of cancer therapy. Initial notable milestones included Bernard Peyrilhe’s first radical mastectomy for breast cancer in 1773 [3], the pioneering use of radiation therapy by Swedish physicians Tor Stenbeck and Tage Sjogren to treat squamous cell carcinoma in 1899 [4], and Roy Hertz and Min Chiu Li’s groundbreaking use of methotrexate to achieve the first complete cure of a human solid tumor in 1953 [5]. However, the progress in developing novel cancer therapies has greatly accelerated since then. With advancements in technology and scientific knowledge, we now have a deeper understanding of the genetic, environmental, physiological, and metabolic factors contributing to cancer initiation and progression. Despite these advances, one of the primary challenges in cancer treatment remains the ability to specifically target cancer cells without h

FAQs

Why are virus-host interaction studies useful for cancer therapy?

Many virus-targeted pathways that support viral replication are also important for cancer growth. Studying these interactions can reveal mechanisms for tumorigenesis and guide development of new anti-cancer therapies.

What anti-cancer properties does the adenoviral E4orf4 protein show?

E4orf4 can selectively kill diverse cancer cell lines while sparing non-cancerous cells, and it can eliminate cancer in an in vivo Drosophila model without causing major harm to normal tissues.

How does the E4orf4-mimicking drug cocktail improve outcomes compared with individual drugs?

Using sublethal doses of four FDA-approved drugs that target pathways disrupted by E4orf4 significantly increases cancer cell death across many cancer cell types compared with single-drug treatment or less inclusive combinations, while remaining non-toxic to non-cancerous cells.

Sep 21, 2026

Uploaded by Valentina